The new article “Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B-Cell Malignancies” by Oleg Demin Jr, Ying Ou, Galina Kolesova, Dmitry Shchelokov, Alexander Stepanov, Veronika Musatova, Sri Sahasranaman, Yating Zhao, Xiangyu Liu, Zhiyu Tang, William D. Hanley was published in CPT: Pharmacometrics & Systems Pharmacology Journal on February 12, 2025. The work was supported by BeiGene.
Oleg Demin Jr, Scientific Director, Oncology & Immuno-Oncology, highlights “The aim of this work was to simulate the target occupancy of three approved covalent BTK inhibitors, not only in PBMC but also in tissues such as lymph nodes and bone marrow. Consistent with observed clinical data, the model predicted that zanubrutinib 160 mg twice daily resulted in higher trough BTK occupancy compared with approved doses of ibrutinib and acalabrutinib. Remarkably, due to the mechanistic description of BTK turnover and its inhibition, the model can potentially be used to simulate target occupancy for reversible BTK inhibitors and even BTK protein levels during treatment with targeted protein degraders. Moreover, BTK occupancy in non-oncology indications can also be predicted. The development of this versatile and highly reproducible model was enabled by the application of our established software infrastructure, namely, the Heta compiler and HetaSimulator.”
Learn more about Heta Project: hetalang.github.io
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | June 2020 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
1.
02 Jun 2020 13:24
InSysBio to announce the launch of QSP model of COVID-19
The new open source project to be developed and updated Online
InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces the launch of its fundamentally new project in response to the ongoing global threat, the open source QSP model of COVID-19. In accordance with its mission, which is to assist pharmaceutical industry to speed up the delivery of the cure to patients, InSysBio team could not stay aside. Thus, the aim of the new project is to develop QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
|
3
|
4
|
5
1.
05 Jun 2020 15:04
InSysBio to present IRT Navigator 3
InSysBio presents IRT Navigator 3 which is an application software providing intuitive interface to work with the Immune Response Template Database in accordance with the user’s needs. It supplies the navigation within the schemes and components and efficient development of QSP models based on IRT Database.
|
6
|
7
|
|
8
1.
08 Jun 2020 15:30
InSysBio to perform the first step in development of COVID-19 QSP model
InSysBio has performed the first step in the direction of development of QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
|
9
|
10
|
11
|
12
1.
12 Jun 2020 16:45
InSysBio to release the new version of Cytocon DB 1.1.6.4
We are glad to announce the release of the new version of Cytocon DB 1.1.6.4. The DB was significantly extended with new data due to well-coordinated workflow of Cytocon DB team and its new members. Namely, 54 diseases, 24 tissues, 42 molecules, 24 cells and 3701 concentrations were introduced.
|
13
|
14
|
|
15
|
16
|
17
1.
17 Jun 2020 15:48
InSysBio to welcome its new team member Dr. Neil Benson
InSysBio announces the appointment of Dr. Neil Benson as Principal Consultant in area of business development
(Edinburgh-Moscow-16.06.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, is proud to announce its new team member Dr. Neil Benson! Dr. Benson has joined InSysBio as Principal Consultant in area of business development of both INSYSBIO LLC and INSYSBIO UK LIMITED. In his capacity as Principal Consultant to InSysBio, he will support further development of the outstanding IO and AD QSP offering of the company.
|
18
|
19
|
20
|
21
|
|
22
1.
22 Jun 2020 17:04
InSysBio team posters to be presented at AACR Virtual Annual Meeting II
AACR Virtual Annual Meeting II has begun! American Association for Cancer Research Annual Meeting is held virtually this year on June 22-24 due to COVID-19 spread. Today InSysBio team's posters were published on AACR website
|
23
|
24
|
25
|
26
|
27
|
28
|
|
29
|
30
1.
30 Jun 2020 15:45
InSysBio to present COVID-19 QSP model further development
InSysBio continues to move forward in COVID-19 QSP model development. Its aim is to describe virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
| |||||
Thank you for your message! We will get back to you shortly.
